Kochi: ICAR-Central Marine Fisheries Research Institute (CMFRI) has developed a nutraceutical product from algae to combat non-alcoholic fatty liver disease (NAFLD). A product called CadalminTM LivCure extract will be released soon. It is protected by patents.
CMFRI has signed a Memorandum of Understanding (MoU) with M/S. Emineotech, a private limited company responsible for health products, for the production and commercial marketing of the product. Dr. A Gopalakrishnan, Director, CMFRI, signed the license agreement with Evangelist Pathrose, Managing Director, Emineotech.
A unique blend of 100 percent natural bioactive ingredients extracted from selected algae, the product is made with an eco-friendly green technology to improve liver health, and is the 9th nutraceutical developed by CMFRI, the institute said in a press release.
CMFRI has already commercialized nutraceuticals to address lifestyle diseases such as type 2 diabetes, arthritis, cholesterol, hypertension, hypothyroidism and osteoporosis, in addition to boosting immunity.
“Since CMFRI developed the CadalminTM LivCure extract we have been receiving an overwhelming response from the public, which shows the growing demand for natural remedies for lifestyle diseases,” said Dr. Gopalakrishnan.
“The commercialization of the product will be of great benefit to people with non-alcoholic fatty liver disease as it helps improve liver health, reduce fat disposal and maintain other liver/lipid parameters within clinically acceptable limits.” he said
“Aware of the great pharmaceutical and medicinal potential of seaweed, CMFRI put efforts towards large-scale cultivation of seaweed across the coastal states of the country,” added Dr. Gopalakrishnan.
Dr. Kajal Chakraborty, Principal Scientist, Division of Marine Biotechnology, Fish Nutrition and Health, CMFRI led the research work for the development of the product.
The product will hit the market in four months and will be available for online sale on Amazon, Flipkart and other leading e-commerce platforms, in addition to physical market networks across the country, said Emineotech managing director Evanjalist Pathrose.
He said the company will introduce initiatives to create community awareness about asymptomatic fatty liver disease and the benefits of natural remedies, including lifestyle changes.